Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period

Journal of Association of Physicians of India

Volumn 54, Issue FEB., 2006, Pages 133-142

  Das, U N ^a  

^a UND LIFE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; SUPEROXIDE;

ARTICLE; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PUERPERIUM;

FEMALE; HOMOCYSTEINE; HUMANS; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; POSTPARTUM PERIOD; PREGNANCY; SUPEROXIDES;

EID: 32044439872     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Kumar KV and Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Rad Res Commun 1993;19:59-66.
2. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, Salvetti A. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001;38:274-79.
3. Suryaprabha P, Das UN, Koratkar R, Sangeetha P, Ramesh G. Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled hypertension. Prostaglandins Leukot Essen Fatty Acids 1990;41:27-33.
4. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium derived contracting factor. Am J Physiol 1989;257:433-37.
5. Nakazono L, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does Superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991;88:10045-48.
6. Jun T, Ke-Yan F, Catalano M. Increased Superoxide anion production in humans: a possible mechanism for the pathogenesis of hypertension. J Hum Hypertens 1996;10: 305-9.
7. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension 2001;37(2 part 2):529-34.
8. Carneado J, Alvarez de Sotomayor M, Perez-Guerrero C, Jimmenez L, Herrera MD, Pamies E, Martin-Sanz MD, Stiefel P, Miranda M, Bravo L, Marhuenda E. Simvastatin improves endothelial function in spontaneously hypertensive rats through a Superoxide dismutase mediated antioxidant effect. J Hypertens 2002;20:429-37.
9. El Midaoui A, Wu R, De Champlain J. Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens 2002;20:1407-12.
10. Das UN. Can COX-2 inhibitors-induced increase in cardiovascular disease risk be modified by essential fatty acids? J Assoc Physicians India 2005;53:623-27.
11. Das UN. Clinical laboratory tools to diagnose inflammation. In Advances in Clinical Chemistry, in press.
12. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont FJ, Diez J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001;38:1395-99.
13. Morawietz H, Weber M, Rueckschloss U, Lauer N, Hacker A, Kojda G. Upregulation of vascular NAD(P)H oxidase subunit gp91phox and impairment of the nitric oxide signal transduction pathway in hypertension. Biochem Biophys Res Commun 2001;285:1130-35.
14. Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, Takeshita A. Chronic inhibition of nitric oxide synthesis in rats increases aortic Superoxide anion production via the action of angiotensin II. J Hypertens 2000;18:1795-1800.
15. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, Daniel WG. Angiotensin II-induced Superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-NAD(P)H-oxidases. Cardiovasc Res 1999;44:215-22.
16. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 2001;89:408-14.
17. Guzik TJ, West NE, Pillai R, Taggart DP, Channon KM. Nitric oxide modulates Superoxide release and peroxynitrite formation in human blood vessels. Hypertension 2002;39:1088-94.
18. Kaehler J, Sill B, Koester R, Mittmann C, Orzechowski HD, Muenzel T, Meinertz T. Endotelin-1 mRNA and protein in vascular wall cells is increased by reactive oxygen species. Clin Sci (Lond) 2002;103 suppl 1:176S-178S.
19. Smith AP, Demoncheaux EA, Higenbottam TW. Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells. Nitric Oxide 2002;6:153-59.
20. rd, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 1998;97:851-56.
21. Takahashi H, Hara K, Komiyama Y, Masuda M, Murakami T, Nishimura M, Nambu A, Yoshimura M. Mechanism of hypertension induced by chronic inhibition of nitric oxide in rats. Hypertension Res 1995;18:319-24.
22. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993;11:1375-80.
23. Bachmann S, Mundel P. Nitric oxide in the kidney: synthesis, localization, and function. Am J Kidney Dis 1994;24:112-29.
24. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000;101:856-61.
25. Diederich D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of Superoxide. Hypertension 1994;23(3 Pt 2):957-61.
26. Das UN. Nutritional factors in the pathobiology of human essential hypertension. Nutrition 2001;17:337-46.
27. Passmore JC, Hatton DC, McCarron DA. Dietary calcium decreases blood pressure without decreasing renal vascular resistance or altering the response to NO blockade. J Lb Clin Med 1997;130:627-34.
28. Schmidt RJ, Beierwaltes WH, Baylis C. Effects of aging and alterations in dietary sodium intake on total nitric oxide production. Am J Kidney Dis 2001;37:900-8.
29. Tan DY, Meng S, Cason GW, Manning RD Jr. Mechanisms of salt-sensitive hypertension: role of inducible nitric oxide synthase. Am J Physiol Regul Comp Physiol 2000;279:R2297-R2303.
30. Campese VM, Amar M, Anjali C, Medhat T, Wurgaft A. Effect of L-arginine on systemic and renal haemodynamics in salt-sensitive patients with essential hypertension. J Hum Hypertens 1997;11:527-32.
31. Bayorh MA, Williams E, Thierry-Palmer M, Sanford G, Emmett N, Harris-Hooker S, Socci RR, Chu TC. Enhanced nitric oxide synthesis reverses salt-induced alterations in blood flow and cGMP levels. Clin Exp Hypertens 1999;21: 333-52.
32. Taddei S, Mattei P, Virdis A, Sudano L, Ghiadoni L, Salvetti A. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 1994;23:485-90.
33. Das UN. Minerals, trace elements, and vitamins interact with essential fatty acids and prostaglandins to prevent hypertension, thrombosis, hypercholesterolemia, and atherosclerosis and their attendant complications. IRCS Med Sci 1985;13:684-88.
34. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998;98:1842-47.
35. Zoccali C, Bode-Boger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Fermo I, Frolich JC, Boger RH. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-17.
36. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001;358:2096-97.
37. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-58.
38. Valkonen V-P, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentrations of asymmetrical dimethylarginine. Lancet 2001;358:2127-28.
39. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996;94:1298-1303.
40. McAllister AS, Atkinson AB, Johnston GD, Hadden DR, Bell PM, McCance DR. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond) 1999;97:141-47.
41. Kohno M, Yokokawa K, Minami M, Yasunari K, Maeda K, Kano H, Hanehira T, Yaoshikawa J. Plasma levels of nitric oxide and related vasoactive factors following long-term treatment with angiotensin-converting enzyme inhibitor in patients with essential hypertension. Metabolism 1999;48:1256-59.
42. Takase H, Sugiyama M, Nakazawa A, Sato K, Ueda R, Dohi Y. Long-term effect of antihypertensive therapy with calcium antagonist or angiotensin converting enzyme inhibitor on serum nitrite/nitrate levels in human essential hypertension. Arzneimittelforschung 2000;50:530-34.
43. Kumar KV and Das UN. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin converting enzyme activity in vitro. Proc Exp Biol Med 1997;214:374-79.
44. Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 2000;97:3479-84.
45. Derhaschnig U, Shehata M, Herkner H, Bur A, Woisetschlager C, Laggner AN, Hirschl MM. Increased levels of transforming growth factor-beta 1 in essential hypertension. Am J Hypertens 2002;15:207-11.
46. Yamada Y, Fujisawa M, Ando F, Niino N, Tanaka M, Shimokata H. Association of a polymorphism of the transforming growth factor-beta 1 gene with blood pressure in Japanese individuals. J Hum Genet 2002;47:243-48.
47. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care. 2002;25:1072-77.
48. Russo LM, Osicka TM, Bonnet F, Jerums G, Comper WD. Albuminuria in hypertension is linked to altered lysosomal activity and TGF-beta 1 expression. Hypertension 2002;39:281-86.
49. Wong VY, Laping NJ, Nelson AH, Contino LC, Olson B A, Gygielko E, Cambell WG Jr, Barone F, Brooks DP. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacal 2001;134:977-84.
50. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-betal and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001;16Suppl 1:90-93.
51. Dhaly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, Roman RJ. Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats. Am J. Physiol Regul Integr Comp Physiol 2002;283:R757-67.
52. Riser BL, Cortes P, Yee J, Sharba AK, Asano K, Rodriguez-Barbero A, Narins RG. Mechanical strain- and high-glucose induced alterations in mesangial cell collagen metabolism: role of TGF-beta. J Am Soc Nephrol 1998;9:827-36.
53. Das UN. Biological significance of arachidonic acid. Med Sci Res 1987;24:1485-89.
54. Shin GT, Khanna A, Ding R, Sharma VK, Lagman M, Li B, Suthanthiran M. In vivo expression of transforming growth factor-betal in humans: stimulation by cyclosporine. Transplantation 1998;65:313-18.
55. Ying WZ, Sanders PW. Dietary salt increases endothelial nitric oxide synthase and TGF-beta in rat aortic endothelium. Am J Physiol 1999;277(4 Ft 2): H1293-98.
56. Trachtman H, Koss I, Bogart M, Abramowitz J, Futterweit S, Franki N, Singhal PC. High glucose enhances growth factor-stimulated nitric oxide production by cultured rats mesangial cells. Res Commun Mol Pathol Pharmacol 1998;100:213-25.
57. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 1997;46:671-81.
58. Studer RK, Georgescu HI, Miller LA, Evans CH. Inhibition of transforming growth factor beta production by nitric oxidetreated chondrocytes: implications for matrix synthesis. Arthritis Rheum 1999;42:248-57.
59. Koide M, Kawahara Y, Tsuda T, Nakayama I, Yokoyama M. Expression of nitric oxide synthase by cytokines in vascular smooth muscle cells. Hypertension 1994;23(1 Suppl):145-48.
60. Das UN. Essential fatty acids: biology and their clinical implications. Asia Pacific J Pharmacol 1991;6:317-30.
61. Das UN, Horrobin DF, Begin ME, Huang YS, Cunnane SC, Manku MS. Clinical significance of essential fatty acids. Nutrition 1988;4:337-42.
62. Das UN. Essential fatty acids in health and disease. J Assoc Physicians India 1999;47:906-11.
63. Das UN. Biological significance of arachidonic acid. Med Sci Res 1987;24:1485-89.
64. McVeigh GE, Brennan GM, Johnson GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1993;36:33-38.
65. Mohan IK, Das UN. Prevention of chemically induced diabetes mellitus in experimental animals by polyunsaturated fatty acids. Nutrition 2001;17:126-51.
66. Mohan IK, Das UN. Effect of L-arginine-nitric oxide system on the metabolism of essential fatty acids in chemical-induced diabetes mellitus. Prostaglandins Leukot Essen Fatty Acids 2000;62:35-46.
67. Das UN. Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus, and coronary heart disease. Prostaglandins Leukot Essen Fatty Acids 1995;52: 387-91.
68. Das UN, Kumar KV, Ramesh G. Essential fatty acid metabolism in South Indians. Prostaglandins Leukot Essen Fatty Acids 1994;50:253-56.
69. Kumar GS, Das UN. Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. Prostaglandins Leukot Essen Fatty Acids 1994;50:331-36.
70. Das UN. Obesity, metabolic syndrome X, and inflammation. Nutrition 2002;18:430-32.
71. Das UN. Is metabolic syndrome X an inflammatory condition? Exp Biol Med 2002;227:989-97.
72. Fernandez-Real JM, Vayreda M, Richart C, et al. Circulating interleukins 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001;86:1154-59.
73. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403.
74. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukins-6, Creactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vase Biol 2002;22:1668-73.
75. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the rennin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.
76. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.
77. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in Superoxide production and modification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262:10098-103.
78. Wall RT, Harlan JM, Harker LA, Striker GE. Homocyst(e)ineinduced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1986;18:113-121.
79. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Single D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
80. Upchurch GR, Welch GN, Freedman JE, Loscalzo J. Homocys(e)ine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated cell injury. Circulation 1995;92:I-228.
81. Tsai J.-C, Perrella MA, Yoshizumi M, Hseih CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocyst(e)ine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
82. Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vase Biol 2002;22:699-703.
83. 6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001;103: 2788-91.
84. Das UN. Pyridoxine, thrombosis and prostaglandins. Lancet 1981;ii:638.
85. Das UN. Hemostatic vitamins and prostaglandins. Med J Australia 1982;2:316.
86. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS. Homocysteine induces 3-hydroxy-3-methylglutaryl coenzyme A reductase in vascular endothelial cells. Circulation 2002;105:1037-43.
87. Das UN. Is insulin an anti-inflammatory molecule? Nutrition 2001;17:409-13.
88. Guidot DM, Hybertson BM, Kitlowski RP, Repine JE. Inhaled nitric oxide prevents IL-1 induced neutrophil accumulation and associated acute edema in isolated rat lungs. Am J Physiol 1996;271:1225-29.
89. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolic acid, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237-41.
90. Verma S, Dumont AS, Maitland A. Tetrahydrobiopterin attenuates cholesterol induced coronary hyperreactivity to endothelin. Heart 2001;86:706-8.
91. Huang A, Vita JA, Venema RC, Keaney JF Jr. Ascorbic acid enhances endothelial nitric oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000;275:17399-406.
92. Baker TA, Milstien S, Katusic ZS. Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. J Cardiovasc Pharmacol 2001;37:333-38.
93. Tyurin VA, Liu S-X, Tyurina YY, Sussman NB, Hubel CA, Roberts JM, Taylor RN, Kagan VE. Elevated levels of Snitrosoalbumin in preeclampsia plasma. Circulation Res 2001;88:1210-15.
94. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996;94:1298-1303.
95. McAllister AS, Atkinson AB, Johnston GD, Hadden DR, Bell PM, McCance DR. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond) 1999;97:141-47.
96. Singhal A, Cole TJ, Lucas A. Early nutrition in preterm infants and later blood pressure: two cohorts after randomized trials. Lancet 2001;357:413-19.
97. Das UN. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevent hypertension in adult life? Hypertension 2001;38: e6-e8.
98. McCarron DA, Morris CD, Henry HJ, Santon JL. Blood pressure and nutrient intake in the United States. Science 1984;224:1392-98.
99. Das UN. A perinatal strategy for preventing adult disease: The role of long-chain polyunsaturated fatty acids. Kluwer Academic Publishers, Boston, 2002.